麝香保心丸联合辛伐他汀对冠心病心绞痛患者血清IL-18、VEGF、T-SOD水平的影响

Effect of Shexiang Baoxin Pill(麝香保心丸) Combined with Simvastatin on Serum Levels of IL-18,VEGF and T-SOD in Patients with Coronary Heart Disease and Angina Pectoris

目的研究麝香保心丸联合辛伐他汀对冠心病心绞痛患者血清白细胞介素-18(IL-18)、血管内皮生长因子(VEGF)、总超氧化物歧化酶(T-SOD)水平的影响。方法选择2018年3月—2020年8月医院收治的150例冠心病心绞痛患者为研究对象,分对照组和研究组各75例,对照组患者口服辛伐他汀,研究组在对照组基础上服用麝香保心丸,两组均连续治疗6个月,观察比较两组:(1)治疗后临床疗效及心电图疗效,(2)治疗前后中医证候积分、生化指标[IL-18、VEGF、T-SOD、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(DHL)、低密度脂蛋白(LDL)、纤维蛋白原]水平、血浆黏度、心绞痛改善情况,(3)不良反应发生情况。结果治疗后,研究组临床治疗总有效率为(82.67%,62/75)和心电图总有效率(89.33%,67/75)明显高于对照组总有效率[54.67%(41/75)、69.33%(52/75)](P<0.05);治疗前,两组中医证候积分、各生化指标水平、血浆黏度、心绞痛积分、持续时间及发作频率比较差异无统计学意义(P>0.05);治疗后,两组患者中医证候积分、IL-8、LDL、TG、TC水平、纤维蛋白原水平及血浆黏度值、心绞痛积分、持续时间及发作频率较本组治疗前明显下降,较本组治疗前明显下降(P<0.05),两组患者VEGF、T-SOD、HDL水平较本组治疗前明显升高(P<0.05),研究组中医证候积分、IL-8水平、LDL、TG、TC水平、纤维蛋白原水平及血浆黏度值、心绞痛积分、持续时间及发作频率明显小于对照组(P<0.05);治疗后,研究组VEGF、T-SOD、HDL水平明显高于对照组(P<0.05);治疗后,研究组总不良反应发生率(4.00%,3/75)与对照组总不良反应发生率5.33%(4/75)比较差异无统计学意义(P>0.05)。结论麝香保心丸联合辛伐他汀治疗冠心病心绞痛疗效显著,能有效调节血脂水平和心血管相关指标水平,减小患者心绞痛积分、持续时间及发作频率,且不良反应发生率较低,值得临床推广。

Objective To investigate the effect of Shexiang Baoxin Pill(麝香保心丸)combined with simvastatin on serum levels of IL-18,VEGF and T-SOD in patients with coronary heart disease and angina pectoris.Methods A total of 150 patients with coronary heart disease and angina pectoris admitted to our hospital from March 2018 to August 2020 were selected and divided into two groups,each with 75 cases.The control group received the simvastatin.Based on this,the study group received Shexiang Baoxin Pill and the treatment in both groups lasted for 6 courses.Then various indexes were compared between groups,including clinical efficacy,ECG efficacy,TCM syndrome scores,biochemical indicators[interleukin 18(IL-18),vascular endothelial growth factor(VEGF),total superoxide dismutase(T-SOD),triglyceride(TG),total cholesterol(TC),high density lipoprotein(DHL),low density lipoprotein(LDL),fibrinogen]levels,plasma viscosity,angina pectoris and adverse reactions.Results The total effective rate and ECG efficacy of the study group were significantly higher than those of the control group[82.67%(52/75)vs 54.67%(41/75),89.33%(67/75)vs 69.33%(52/70),P<0.05)].The TCM syndrome scores,levels of IL-8,LDL,TG and TC,fibrinogen,plasma viscosity values,score,duration and seizure frequency of angina showed no difference between the two groups before treatment(P>0.05).After treatment,the TCM syndrome scores,levels of IL-8,LDL,TG and TC,fibrinogen,plasma viscosity,scores,duration and frequency of onsets were decreased in both groups and were lower in the study group than those in the control group(P<0.05).Meanwhile,the levels of VEGF,T-SOD and HDL were increased in both groups and were higher in the study group than those in the control group(P<0.05).After treatment,the incidence of total adverse reactions showed no difference between groups(4.00%(3/75)vs 5.53%(4/75),P>0.05).Conclusion The application of Shexiang Baoxin Pill combined with simvastatin can effectively regulate blood lipid levels and cardiovascular related indicators,reduce the duration and frequency of angina pectoris with fewer adverse reactions,which is worthy of clinical promotion.